Log In
BCIQ
Print this Print this
 

fipamezole (JP-1730)

  Manage Alerts
Collapse Summary General Information
Company Santhera Pharmaceuticals Holding AG
DescriptionAdrenergic receptor alpha 2 (ADRA2) antagonist
Molecular Target Adrenergic receptor alpha 2 (ADRA2)
Mechanism of ActionAdrenergic receptor alpha 2 (ADRA2) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHyperkinetic movement disorder
Indication DetailsTreat dyskinesia in Parkinson's disease (DPD) patients associated with late stage Parkinson's disease; Treat dyskinesia in Parkinson's disease (PD) patients
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$394.6M

$28.5M

$362.9M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today